BC Week In Review | Apr 20, 2017
Clinical News

ApoGraft: Ph I/II ApoGraft01 ongoing

An independent DSMB approved the enrollment of the next 2 patients in the first cohort of the open-label, Israeli Phase I/II ApoGraft01 trial evaluating transplanted ApoGraft exposed to FASL. The DSMB made the recommendation after...
BC Week In Review | Feb 9, 2017
Clinical News

ApoGraft: Ph I/II started

Cellect began an open-label, Israeli Phase I/II trial to evaluate transplanted ApoGraft exposed to 10, 25, 50 or 100 ng/mL FASL in about 12 patients undergoing allogeneic stem cell transplantation (ASCT) from a matched related...
BC Week In Review | Dec 2, 2016
Company News

Cellect, Hadassah deal

Hadassah's Hadasit Ltd. technology transfer arm partnered with Cellect to conduct preclinical studies of Cellect’s ApoGraft to treat graft-versus-host disease (GvHD). Hadassah will conduct the studies. ApoGraft consists of mobilized peripheral blood cells (MPBC) for...
Items per page:
1 - 3 of 3